The effects of naltrexone among alcohol non-abstainers: Results from the COMBINE Study

Frontiers in Psychiatry

Volumn 1, Issue OCT, 2010, Pages

  Ray, Lara A ^a   Krull, Jennifer L ^a   Leggio, Lorenzo ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BROWN UNIVERSITY   (United States)

Author keywords

Abstainer; Alcoholism; Combine study; Heavy drinking; Naltrexone

Indexed keywords

EID: 79960345889     PISSN: None     EISSN: 16640640     Source Type: Journal    
DOI: 10.3389/fpsyt.2010.00026     Document Type: Article

References (56)

1. Anton, R. F., Drobes, D. J., Voronin, K., Durazo-Avizu, R., and Moak, D. (2004). Naltrexone effects on alcohol consumption in a clinical laboratory paradigm: temporal effects of drinking. Psychopharmacology (Berl.) 173, 32-40.
2. Anton, R. F., Kranzler, H. R., and Meyer, R. E. (1995). Neurobehavioral aspects of the pharmacotherapy of alcohol dependence. Clin. Neurosci. 3, 145-154.
3. Anton, R. F., Moak, D. H., Waid, L. R., Latham, P. K., Malcolm, R. J., and Dias, J. K. (1999). Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: results of a placebo-controlled trial. Am. J. Psychiatry 156, 1758-1764.
4. Anton, R. F., O'Malley, S. S., Ciraulo, D. A., Cisler, R. A., Couper, D., Donovan, D. M., Gastfriend, D. R., Hosking, J. D., Johnson, B. A., LoCastro, J. S., Longabaugh, R., Mason, B. J., Mattson, M. E., Miller, W. R., Pettinati, H. M., Randall, C. L., Swift, R., Weiss, R. D., Williams, L. D., and Zweben, A. (2006). Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA 295, 2003-2017.
5. Anton, R. F., Oroszi, G., O'Malley, S., Couper, D., Swift, R., Pettinati, H., and Goldman, D. (2008). An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. Arch. Gen. Psychiatry 65, 135-144.
6. Balldin, J., Berglund, M., Borg, S., Mansson, M., Bendtsen, P., Franck, J., Gustafsson, L., Halldin, J., Nilsson, L. H., Stolt, G., and Willander, A. (2003). A 6-month controlled naltrexone study: combined effect with cognitive behavioral therapy in outpatient treatment of alcohol dependence. Alcohol. Clin. Exp. Res. 27, 1142-1149.
7. Bouza, C., Angeles, M., Munoz, A., and Amate, J. M. (2004). Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review. Addiction 99, 811-828.
8. Chick, J., Anton, R., Checinski, K., Croop, R., Drummond, D. C., Farmer, R., Labriola, D., Marshall, J., Moncrieff, J., Morgan, M. Y., Peters, T., and Ritson, B. (2000). A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse. Alcohol Alcohol. 35, 587-593.
9. COMBINE Study. (2003a). Testing combined pharmacotherapies and behavioral interventions for alcohol dependence: a pilot feasibility study. Alcohol. Clin. Exp. Res. 27, 1123-1131.
10. COMBINE Study. (2003b). Testing combined pharmacotherapies and behavioral interventions in alcohol dependence: rationale and methods. Alcohol. Clin. Exp. Res. 27, 1107-1122.
11. Crews, F. T., and Boettiger, C. A. (2009). Impulsivity, frontal lobes and risk for addiction. Pharmacol Biochem Behav. 93, 237-247.
12. Davidson, D., Swift, R., and Fitz, E. (1996). Naltrexone increases the latency to drink alcohol in social drinkers. Alcohol. Clin. Exp. Res. 20, 732-739.
13. Drobes, D. J., Anton, R. F., Thomas, S. E., and Voronin, K. (2004). Effects of naltrexone and nalmefene on subjective response to alcohol among non-treatment-seeking alcoholics and social drinkers. Alcohol. Clin. Exp. Res. 28, 1362-1370.
14. FDA. (2006). Medical Review of Vivitrol. Rockville, MD: Government, U.S.
15. Guardia, J., Caso, C., Arias, F., Gual, A., Sanahuja, J., Ramirez, M., Mengual, I., Gonzalvo, B., Segura, L., Trujols, J., and Casas, M. (2002). A double-blind, placebo-controlled study of naltrexone in the treatment of alcohol-dependence disorder: results from a multicenter clinical trial. Alcohol. Clin. Exp. Res. 26, 1381-1387.
16. Gueorguieva, R., Wu, R., Pittman, B., Cramer, J., Rosenheck, R. A., O'Malley S, S., and Krystal, J. H. (2007). New insights into the efficacy of naltrexone based on trajectory-based reanalyses of two negative clinical trials. Biol. Psychiatry 61, 1290-1295.
17. Heinala, P., Alho, H., Kiianmaa, K., Lonnqvist, J., Kuoppasalmi, K., and Sinclair, J. D. (2001). Targeted use of naltrexone without prior detoxification in the treatment of alcohol dependence: a factorial double-blind, placebo-controlled trial. J. Clin. Psychopharmacol. 21, 287-292.
18. Kemper, A., Koalick, F., Thiele, H., Retzow, A., Rathsack, R., and Nickel, B. (1990). Cortisol and beta-endorphin response in alcoholics and alcohol abusers following a high naloxone dosage. Drug Alcohol Depend. 25, 319-326.
19. Kiefer, F., Jahn, H., Tarnaske, T., Helwig, H., Briken, P., Holzbach, R., Kampf, P., Stracke, R., Baehr, M., Naber, D., and Wiedemann, K. (2003). Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study. Arch. Gen. Psychiatry 60, 92-99.
20. King, A. C., Volpicelli, J. R., Frazer, A., and O'Brien, C. P. (1997). Effect of naltrexone on subjective alcohol response in subjects at high and low risk for future alcohol dependence. Psychopharmacology (Berl.) 129, 15-22.
21. Koob, G. F. (1992). Drugs of abuse: anatomy, pharmacology and function of reward pathways. Trends Pharmacol. Sci. 13, 177-184.
22. Koob, G. F., and Le Moal, M. (2008). Addiction and the brain antireward system. Annu. Rev. Psychol. 59, 29-53.
23. Kranzler, H. R., Modesto-Lowe, V., and Van Kirk, J. (2000). Naltrexone vs. nefazodone for treatment of alcohol dependence. A placebo-controlled trial. Neuropsychopharmacology 22, 493-503.
24. Kranzler, H. R., Stephenson, J. J., Montejano, L., Wang, S., and Gastfriend, D. R. (2008). Persistence with oral naltrexone for alcohol treatment: implications for health-care utilization. Addiction 103, 1801-1808.
25. Krystal, J. H., Cramer, J. A., Krol, W. F., Kirk, G. F., and Rosenheck, R. A. (2001). Naltrexone in the treatment of alcohol dependence. N. Engl. J. Med. 345, 1734-1739.
26. Latt, N. C., Jurd, S., Houseman, J., and Wutzke, S. E. (2002). Naltrexone in alcohol dependence: a randomised controlled trial of effectiveness in a standard clinical setting. Med. J. Aust. 176, 530-534.
27. Litten, R. Z., Allen, J., and Fertig, J. (1996). Pharmacotherapies for alcohol problems: a review of research with focus on developments since 1991. Alcohol. Clin. Exp. Res. 20, 859-876.
28. Mann, K., Anton, R., Kiefer, F., and Smolka, M. (2007). Are patients in the US treatment trials different from European patients? A comparison between the COMBINE Study and the Project PREDICT. Alcohol. Clin. Exp. Res. 31, 58A.
29. McCaul, M. E., Wand, G. S., Eissenberg, T., Rohde, C. A., and Cheskin, L. J. (2000). Naltrexone alters subjective and psychomotor responses to alcohol in heavy drinking subjects. Neuropsychopharmacology 22, 480-492.
30. McCaul, M. E., Wand, G. S., Stauffer, R., Lee, S. M., and Rohde, C. A. (2001). Naltrexone dampens ethanol-induced cardiovascular and hypothalamic-pituitary-adrenal axis activation. Neuropsychopharmacology 25, 537-547.
31. Miller, W. R., and Del Boca, F. K. (1994). Measurement of drinking behavior using the Form 90 family of instruments. J. Stud. Alcohol Suppl. 12, 112-118.
32. Monti, P. M., Rohsenow, D. J., Swift, R. M., Gulliver, S. B., Colby, S. M., Mueller, T. I., Brown, R. A., Gordon, A., Abrams, D. B., Niaura, R. S., and Asher, M. K. (2001). Naltrexone and cue exposure with coping and communication skills training for alcoholics: treatment process and 1-year outcomes. Alcohol. Clin. Exp. Res. 25, 1634-1647.
33. Morley, K. C., Teesson, M., Reid, S. C., Sannibale, C., Thomson, C., Phung, N., Weltman, M., Bell, J. R., Richardson, K., and Haber, P. S. (2006). Naltrexone versus acamprosate in the treatment of alcohol dependence: a multi-centre, randomized, double-blind, placebo-controlled trial. Addiction 101, 1451-1462.
34. Morris, P. L., Hopwood, M., Whelan, G., Gardiner, J., and Drummond, E. (2001). Naltrexone for alcohol dependence: a randomized controlled trial. Addiction 96, 1565-1573.
35. Myrick, H., Anton, R. F., Li, X., Henderson, S., Randall, P. K., and Voronin, K. (2008). Effect of naltrexone and ondansetron on alcohol cue-induced activation of the ventral striatum in alcohol-dependent people. Arch. Gen. Psychiatry 65, 466-475.
36. Naber, D., Pickar, D., Davis, G. C., Cohen, R. M., Jimerson, D. C., Elchisak, M. A., Defraites, E. G., Kalin, N. H., Risch, S. C., and Buchsbaum, M. S. (1981). Naloxone effects on beta-endorphin, cortisol, prolactin, growth hormone, HVA and MHPG in plasma of normal volunteers. Psychopharmacology (Berl.) 74, 125-128.
37. O'Brien, C. P. (2008). Prospects for a genomic approach to the treatment of alcoholism. Arch. Gen. Psychiatry 65, 132-133.
38. O'Malley, S. S., and Froehlich, J. C. (2003). Advances in the use of naltrexone: an integration of preclinical and clinical findings. Recent Dev. Alcohol. 16, 217-245.
39. O'Malley, S. S., Jaffe, A. J., Chang, G., Schottenfeld, R. S., Meyer, R. E., and Rounsaville, B. (1992). Naltrexone and coping skills therapy for alcohol dependence. A controlled study. Arch. Gen. Psychiatry 49, 881-887.
40. O'Malley, S. S., Krishnan-Sarin, S., Farren, C., Sinha, R., and Kreek, M. J. (2002). Naltrexone decreases craving and alcohol self-administration in alcohol-dependent subjects and activates the hypothalamo-pituitary-adrenocortical axis. Psychopharmacology (Berl.) 160, 19-29.
41. Oslin, D. W., Berrettini, W., Kranzler, H. R., Pettinati, H., Gelernter, J., Volpicelli, J. R.,and O'Brien, C. P. (2003). A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology 28, 1546-1552.
42. Petrakis, I. L., O'Malley, S., Rounsaville, B., Poling, J., McHugh-Strong, C., and Krystal, J. H. (2004). Naltrexone augmentation of neuroleptic treatment in alcohol abusing patients with schizophrenia. Psychopharmacology (Berl.) 172, 291-297.
43. Pettinati, H. M., Oslin, D. W., Kampman, K. M., Dundon, W. D., Xie, H., Gallis, T. L., Dackis, C. A., and O'Brien, C. P. (2010). A double-blind, placebo-controlled trial combining sertraline and naltrexone for treating co-occurring depression and alcohol dependence. Am. J. Psychiatry. 167, 668-675.
44. Pettinati, H. M., O'Brien, C. P., Rabinowitz, A. R., Wortman, S. P., Oslin, D. W., Kampman, K. M., and Dackis, C. A. (2006). The status of naltrexone in the treatment of alcohol dependence: specific effects on heavy drinking. J. Clin. Psychopharmacol. 26, 610-625.
45. Ray, L. A., and Hutchison, K. E. (2007). Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response: a double-blind placebo-controlled study. Arch. Gen. Psychiatry 64, 1069-1077.
46. Ray, L. A., Mackillop, J., Leggio, L., Morgan, M., and Hutchison, K. E. (2009). Effects of naltrexone on cortisol levels in heavy drinkers. Pharmacol. Biochem. Behav. 91, 489-494.
47. Rubio, G., Manzanares, J., Lopez-Munoz, F., Alamo, C., Ponce, G., Jimenez-Arriero, M. A., and Palomo, T. (2002). Naltrexone improves outcome of a controlled drinking program. J. Subst. Abuse Treat. 23, 361-366.
48. Schluger, J. H., Ho, A., Borg, L., Porter, M., Maniar, S., Gunduz, M., Perret, G., King, A., and Kreek, M. J. (1998). Nalmefene causes greater hypothalamic-pituitary-adrenal axis activation than naloxone in normal volunteers: implications for the treatment of alcoholism. Alcohol. Clin. Exp. Res. 22, 1430-1436.
49. Swift, R. M., Whelihan, W., Kuznetsov, O., Buongiorno, G., and Hsuing, H. (1994). Naltrexone-induced alterations in human ethanol intoxication. Am. J. Psychiatry 151, 1463-1467.
50. Tidey, J. W., Monti, P. M., Rohsenow, D. J., Gwaltney, C. J., Miranda, R., Jr., McGeary, J. E., MacKillop, J., Swift, R. M., Abrams, D. B., Shiffman, S.,and Paty, J. A. (2008). Moderators of naltrexone's effects on drinking, urge, and alcohol effects in non-treatment-seeking heavy drinkers in the natural environment. Alcohol. Clin. Exp. Res. 32, 58-66.
51. Tonigan, J. S., Miller, W. R., and Brown, J. M. (1997). The reliability of Form 90: an instrument for assessing alcohol treatment outcome. J. Stud. Alcohol 58, 358-364.
52. Volpicelli, J. R., Alterman, A. I., Hayashida, M., and O'Brien, C. P. (1992). Naltrexone in the treatment of alcohol dependence. Arch. Gen. Psychiatry 49, 876-880.
53. Volpicelli, J. R., Watson, N. T., King, A. C., Sherman, C. E., and O'Brien, C. P. (1995). Effect of naltrexone on alcohol "high" in alcoholics. Am. J. Psychiatry 152, 613-615.
54. Witkiewitz, K. (2008). Lapses following alcohol treatment: modeling the falls from the wagon. J. Stud. Alcohol Drugs 69, 594-604.
55. Zhou, X. H., and Liang, H. (2006). Semi-parametric single-index two-part regression models. Comput. Stat. Data Anal. 50, 1378-1390.
56. Zweben, A., Pettinati, H. M., Weiss, R. D., Youngblood, M., Cox, C. E., Mattson, M. E., Gorroochurn, P., and Ciraulo, D. (2008). Relationship between medication adherence and treatment outcomes: the COMBINE study. Alcohol Clin. Exp. Res. 32, 1661-1669.